Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Active surveillance for intermediate-risk prostate cancer.

Dall'Era MA, Klotz L.

Prostate Cancer Prostatic Dis. 2016 Nov 1. doi: 10.1038/pcan.2016.51. [Epub ahead of print] Review.

PMID:
27801900
2.

Reasons for Abandonment of Active Surveillance in Men with Prostate Cancer.

Dall'Era MA.

J Urol. 2016 Sep;196(3):637-8. doi: 10.1016/j.juro.2016.06.078. No abstract available.

PMID:
27316451
3.

Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry.

Yap SA, Yuh LM, Evans CP, Dall'Era MA, Wagenaar RM, Cress R, Lara PN Jr.

World J Urol. 2016 Jun 15. [Epub ahead of print]

PMID:
27306686
4.

A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.

Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN Jr, Pan CX.

Cancer. 2016 Jun 15;122(12):1897-904. doi: 10.1002/cncr.29927.

PMID:
27019001
5.

Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour.

Pugashetti N, Yap SA, Lara PN Jr, Gandour-Edwards R, Dall'Era MA.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E204-7. doi: 10.5489/cuaj.2447.

6.

Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis.

Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP.

J Urol. 2015 Aug;194(2):304-8. doi: 10.1016/j.juro.2015.02.2948.

7.

Patient and disease factors affecting the choice and adherence to active surveillance.

Dall'Era MA.

Curr Opin Urol. 2015 May;25(3):272-6. doi: 10.1097/MOU.0000000000000154. Review.

PMID:
25692724
8.

Ultrasensitive prostate specific antigen and its role after radical prostatectomy: a systematic review.

Tilki D, Kim SI, Hu B, Dall'Era MA, Evans CP.

J Urol. 2015 May;193(5):1525-31. doi: 10.1016/j.juro.2014.10.087. Review.

PMID:
25444980
9.

Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC.

Eur Urol. 2015 Feb;67(2):241-9. doi: 10.1016/j.eururo.2014.09.007.

10.

Impact of synchronous metastasis distribution on cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy.

Tilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP.

J Urol. 2015 Feb;193(2):436-42. doi: 10.1016/j.juro.2014.07.087.

PMID:
25063493
11.

No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period.

Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA.

Cancer. 2014 Mar 15;120(6):818-23. doi: 10.1002/cncr.28485.

12.

Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus.

Tilki D, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP.

Eur Urol. 2014 Sep;66(3):577-83. doi: 10.1016/j.eururo.2013.06.048.

PMID:
23871402
13.

Validation study of a computer-based open surgical trainer: SimPraxis(®) simulation platform.

Tran LN, Gupta P, Poniatowski LH, Alanee S, Dall'era MA, Sweet RM.

Adv Med Educ Pract. 2013 Mar 19;4:23-30. doi: 10.2147/AMEP.S38422.

14.

The economics of active surveillance for prostate cancer.

Dall'Era MA.

Curr Opin Urol. 2013 May;23(3):278-82. doi: 10.1097/MOU.0b013e32835f4b6b. Review.

PMID:
23449496
15.

Contemporary management of muscle-invasive bladder cancer.

Dall'Era MA, Cheng L, Pan CX.

Expert Rev Anticancer Ther. 2012 Jul;12(7):941-50. doi: 10.1586/era.12.60. Review.

16.

Active surveillance for prostate cancer: a systematic review of the literature.

Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS.

Eur Urol. 2012 Dec;62(6):976-83. doi: 10.1016/j.eururo.2012.05.072. Review.

PMID:
22698574
17.

Economic analysis of active surveillance for localized prostate cancer.

Kim S 2nd, Dall'Era MA, Evans CP.

Curr Opin Urol. 2012 May;22(3):247-53. doi: 10.1097/MOU.0b013e328351dd32. Review.

PMID:
22388666
18.

Active surveillance for prostate cancer compared with immediate treatment: an economic analysis.

Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP.

Cancer. 2012 Jul 15;118(14):3512-8. doi: 10.1002/cncr.26688.

19.

Active surveillance for localized prostate cancer--current practices and recommendations.

Wu JN, Dall'Era MA.

ScientificWorldJournal. 2010 Dec 14;10:2352-61. doi: 10.1100/tsw.2010.227.

20.

Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.

Dall'Era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K, Carroll PR.

BJU Int. 2011 Apr;107(8):1232-7. doi: 10.1111/j.1464-410X.2010.09589.x.

Items per page

Supplemental Content

Loading ...
Support Center